Background: The use of clinical trial registries to signal when systematic reviews become out of date has been limited due to the manual effort required to identify relevant trials. Our aim was to evaluate a new method that could partially automate the identification of trials relevant to a systematic review update. Methods: We identified 179 systematic reviews of drug interventions for type 2 diabetes, linked to 537 trial registrations in ClinicalTrials.gov. Text from the registrations were used as features or transformed using latent Dirichlet allocation or principal component analysis. We tested a shared latent space matrix factorisation method to learn how to rank trial registrations for each systematic review, and compared its performance to baselines that used document similarity. The approaches were tested on a holdout set of trials from the set of type 2 diabetes systematic reviews, and on a set of 17 systematic reviews with updates sourced from the Cochrane Database of Systematic Reviews, linked to 141 clinical trial registrations. The performance was measured by the median rank of relevant trial registrations in the ranked candidate lists and by the number of relevant trial registrations found after examining 100 candidates (recall@100). Results: The matrix factorisation approach outperformed the document similarity approach with a median rank of 36 (of 128,392 candidate registrations in ClinicalTrials.gov) and recall@100 of 75.2%, compared to a median rank of 60 and recall@100 of 60.2% in the document similarity baseline. In the set of systematic reviews and their updates, the highest performing approach used document similarity (median rank 67; recall@100 62.9%). Conclusions: A shared latent space matrix factorisation method was useful for ranking trial registrations to reduce the manual workload associated with finding relevant trials for systematic review updates.
BACKGROUND
S YSTEMATIC reviews of clinical trials are at the foundation of evidence-based medicine and should represent comprehensive, high quality, and up to date syntheses of trial evidence. With the rapid growth of the scientific literature, identifying relevant evidence and keeping systematic reviews up to date is increasingly difficult. Studies examining the timing of systematic reviews suggest that reviews are updated on average every 5.5 years, though a substantial proportion should be updated within 2 years [1] [2] [3] [4] . Performing systematic reviews is time and resource intensive and even determining when a systematic review needs updating often requires completion of the searching and screening steps of the systematic review process. To facilitate this assessment, a number of tools and guidelines have been developed that aim to identify when new relevant research becomes available, or estimate the risk that the results of the systematic review may have substantially changed due to new evidence [3] [4] [5] [6] [7] [8] [9] [10] .
These approaches rely on bibliographic databases, which are limited due to publication and reporting biases that affect the timing and completeness of the results [11] . About half of all trials remain unpublished two years after trial completion, and of those that are published, around half have missing or changed outcomes [12, 13] . As a consequence, bibliographic databases may not provide a complete and timely source of relevant trial evidence for systematic reviews. As various policies and mandates are making prospective trial registration standard practice, clinical trial registries are an increasingly comprehensive and timely source of new research evidence, and in many cases may provide a more complete and less biased record than bibliographic databases [14] . However, the vast majority of methods aiming to support the identification of relevant studies for a systematic review operate over bibliographic databases rather than trial registries [15] and systematic reviews often fail to incorporate any clinical trial registries to identify relevant trials [16] . New methods for identifying relevant trials in clinical trial registries could help determine when systematic reviews need to be updated and support living systematic reviews and automated systematic review updates [17] [18] [19] .
Our aim was to evaluate a new method to partially automate the identification of trials that may be relevant arXiv:1709.06758v1 [cs.IR] 20 Sep 2017 for systematic review updates. This process could serve to signal when a systematic review becomes out of date, based on the amount and type of new evidence that is detected.
RELATED WORK
A number of semi-automated methods have been proposed to identify relevant trials for inclusion in systematic reviews and improve the efficiency of the searching and screening processes [15, 20, 21] . The methods typically use the words or concepts included in the text of published articles to find similarities that are then used to distinguish relevant from irrelevant articles. Some work has also been done to directly extract information on populations, interventions, comparators, and outcomes [22, 23] , which can then be used to match search queries. Several approaches have included the use of active learning [24, 25] , while others have examined representations that use neural network based vector space models [26] . Far less work has been performed on identifying trials from the information stored in clinical trial registries or on linking clinical trial registries to bibliographic databases [14, [27] [28] [29] . However, some methods have shown that it is possible to identify meaningful clusters of similar trials within registries [30] [31] [32] , especially in relation to populations [33] , and ClinicalTrials.gov data has been used in predicting black box warnings [34] .
Matrix factorisation has the potential to support the identification of relevant trials for inclusion in systematic reviews. The approach has a long history of use in addressing problems in link prediction [35] [36] [37] , for example in building systems that recommend books, music, or new social connections to users. This process, commonly referred to as "the item prediction problem", aims to predict the presence or absence of links between the nodes of a graph where the vertices represent users and items, and edges that connect vertices are weighted according to preference scores. Matrix factorisation produces a mapping between users and items into a low-dimensional representation (latent factors) to model the user-item affinity in vector space.
Past work on the use of matrix factorisation for collaborative filtering focused on increasing prediction accuracy by including neighbourhood information [38] . Later, Koren et al. [39] proposed SVD++, a matrix factorisation approach that unified neighbourhood and latent factors. Guo et al. [40] proposed TrustSVD, an extension of SVD++ that incorporates social trust information to help mitigate data sparsity and the cold start problem. TrustSVD includes factorisation of two matrices that share a same latent space -meaning a matrix of user-item preference scores and another matrix that defines trust information among users.
Our proposed matrix factorisation approach shares structural similarity with TrustSVD but applies different regularization methods to adapt to weighted links between systematic reviews and trial registrations. To the best of our knowledge, this is the first study to address the problem of recommending trial registrations for systematic review updates using matrix factorisation with a shared latent space.
MATERIALS AND METHODS

Study data
We searched PubMed and Embase for systematic reviews of drugs used to treat type 2 diabetes. The final search was performed on 26 March 2017, using a search strategy that included terms for type 2 diabetes, type 2 diabetes interventions, and publication type information (see Appendix). Systematic reviews were considered for inclusion in the experiments if they were focused on populations with type 2 diabetes and included at least one meta-analysis ( Figure 1 ). Reviews that summarised or synthesised metaanalyses from other reviews were excluded, as were reviews that did not include full details of a search strategy and did not include at least one meta-analysis of a safety or efficacy outcome. Reviews that also included other populations were included only if they had sub-group analyses that were specific to type 2 diabetes.
After excluding systematic reviews that did not have links to at least 4 trial registrations, we had 179 systematic reviews with 4,447 links to 537 unique trial registrations to form the training and test sets. Trial registrations had a median of 14 links (ranging from 4 to 147) to the systematic reviews.
We accessed ClinicalTrials.gov on May 16, 2017 to create a static local version of information from 128,392 completed trials in order to produce consistent results across all experiments. Information on the brief and official titles, detailed description, inclusion criteria, and intervention names were extracted for use in the experiments.
To test the methods in a general scenario, we additionally identified 17 systematic reviews that were published in the Cochrane Database of Systematic Reviews on any topic. To be included in the experiments, they must have either had an update published with a new search performed before 25 April 2017, or have listed at least three ongoing studies in ClinicalTrials.gov in the published review. We then used the set of included trials as the training set, and the new trials added to the update (or listed as ongoing trials) as the test set. There were 72 unique trials in the original reviews and 69 unique trials in the updates and lists of ongoing relevant trials. The number of trial registrations per systematic review was between 1 and 14 in the original versions and between 1 and 13 in the updates.
Feature representations
Each of the trial registrations was considered as a single document and treated as a bag of words (order was not considered). Each word in the text was converted to lowercase, standard stop words were excluded, the Porter stemmer [41] was applied, and words present in fewer than five trial registrations were excluded. Each trial registration was represented by the set of extracted words from the text after the pre-processing step.
We used multiple feature representations for each trial registration. First, a binary vector representation was created to indicate whether a word feature is present or absent in the text of a trial registration. Secondly, a word frequency vector representation was used to capture the number of times a word feature appears in the text of a trial registration. Lastly, we used a term frequency-inverse document frequency (tf-idf) vector representation, where the entry of the vector is the tf-idf score of a word feature. In the experiments that follow, we refer to these three feature representations as full-dimension feature representations.
We then used principal component analysis (PCA) and Latent Dirichlet Allocation (LDA) to reduce the dimensionality of the feature spaces. The PCA technique transforms data into a lower-dimensional space based on several linearly uncorrelated variables by maximising the variance. We used the implementation of PCA from scikit-learn, and tested it with 20, 50, 100, 200, 300, and 400 components on the tfidf vector representation. The LDA method is a technique that was first introduced to model topics across a set of documents [42, 43] . It uses co-occurrence of words to find latent structures, or topics, in a corpus of documents and a topic is represented by a distribution of word probabilities for that topic. Using LDA, a trial registration is represented by a distribution of topics, where the number of topics is set by parameter. For LDA, we used the gensim implementation with standard settings [44] , and tested it with 20, 50, 100, 200, 300 and 400 topics.
Given a systematic review, one approach to identify relevant trial registrations is to rank all trial registrations according to their similarity with the set of trial registrations for trials included in the review. To determine similarity, we used three document similarity measures: cosine similarity, Euclidean distance, and squared Euclidean distance. These measures were used as a baseline approach against which the matrix factorisation approach was tested.
Matrix factorisation with a shared latent space
Matrix factorisation decomposes a matrix into products of matrices. In our approach, we combine two available sources of information: the text from each trial registration and the links between the trial registrations and the systematic reviews in which they were included. The approach integrates both sources of information via a shared latent space in the learning process to rank all other trial registrations relative to the systematic reviews.
Given U trial registrations and V systematic reviews, where each trial registration is represented by an Jdimensional feature vector extracted from its text and an Vdimensional binary vector to denote the absence or present of a link between a trial registration and a systematic review, we created two matrices: a matrix of trial registrationsfeatures, R ∈ R U ×J ; and a matrix of trial registrationssystematic reviews, T ∈ {0,1} U ×V . Given K latent factors (where K J and K V ), matrices R and T are then decomposed into the following:
In these equations, P is a matrix of trial registrationlatent factors, Q is a matrix of trial registration feature-latent factors and W is a matrix of systematic review-latent factors ( Figure 2 ).
Note that the matrix P is shared and used to connect both R and T in the decomposition process. In other words, the matrix P will describe how trial registrations are associated with systematic reviews based on the features of trial registrations. The goal of matrix factorisation is then to learn matrices P , Q, and W . Once the matrices are learnt, their respective dot products approximate values in matrices R and T ; i.e.R ≈ P Q andT ≈ P W . For the unknown values in matrix T where link information between trial registrations and systematic reviews is not present, the respective approximated values in matrixT are used as a measure of similarity that can then be used to rank unknown trial registrations for each systematic review.
Because the matrix of trial registrations-features, R ∈ R U ×J , is decomposed into a matrix of trial registrationlatent factor P ∈ R U ×K and a matrix of trial registration feature-latent factor Q ∈ R J×K , the loss function that we need to minimise is as follows [37, 40] :
where || · || represents the Frobenius norm, λ is the regularization parameter, r uj is the entry of matrix R in row u and column j, andr uj = p u q j . p u and q j represent Kdimensional vector of trial registration u and its feature j respectively. In a similar way, the matrix of (trial registrationssystematic reviews), T ∈ {0,1} U ×V , is decomposed into a matrix of (trial registration-latent factor) P ∈ R U ×K and a matrix of (systematic review-latent factor) W ∈ R V ×K , and the loss function to minimise is as follows:
where T u represents a set of systematic reviews that a trial registration belongs to, t uv is the entry of matrix T in row u and column v, andt uv = p u w v . p u and w v represent K-dimensional vector of trial registration u and systematic review v respectively. Because matrix is shared in Equation 1 and 2, the new objective function to minimise is then given as follows:
We performed gradient descent on p u , q j and w v based on the final loss function in Equation 3 described in the following equations:
where e uj =r uj −r uj represents the feature prediction error for trial registration u on feature j, and e uv =t uv − t uv represents the link prediction error for trial registration u and systematic review v. We used 5,000 as our maximum number of iterations for the learning process. We calculated root-mean-square error (RMSE) in each iteration during the learning process and returned the results from the learning process when the RMSE was the lowest. We implemented our matrix factorisation approach in Cython. We performed the experiments with λ=0.01, λ t =0.01, and the number of latent factors was set to 5, 10, 20, 30, 40, and 50. The source code of the proposed matrix factorisation approach has been made available (https://github.com/dsurian/matfac).
Experiments and outcome performance measures
For each systematic review, we split the set of links between included trials and systematic reviews into training and test sets with a minimum of 3 links included in the training for each systematic review, and kept this set constant for all experiments. Because systematic reviews had a different number of included trials, the training set included between 3 and 89 links (a median of 9) per systematic review, and a test set with between 1 and 58 links (a median of 5) per systematic review. In the Cochrane systematic reviews, the training set comprised the set of trials included in the systematic reviews (between 1 and 14 links) and the test set comprised the set of trials included in the update of the systematic reviews (between 1 and 13 links).
In each experiment and for each systematic review we produced a ranking for all 128,392 completed ClinicalTrials.gov registrations, and identified where the test links for that systematic review were found in the rankings. For each experiment, the aim was to rank the links from the test set as high as possible within the full set of candidates. The links corresponding to the training set were not included in the ranking and did not contribute to the performance measures.
We calculated the median rank of the trials in the test set by aggregating the ranks of all of the links in the test set and taking the median (i.e. each trial-systematic review link contributed one score and the median rank was calculated from all of its scores). Using that approach, if we were to assign a random rank to all of the trials in the test set, the median rank would converge to approximately 64,196.
We also evaluated the proportion of links in the test set that were included in the first 100 candidates in each of the ranked lists (recall@100), and produced a function for the general version of the same measure (recall@N). The recall@N function can be used to determine the number of candidates that need to be examined per systematic review to identify a given proportion of relevant trial registrations. 
RESULTS
Document similarity performance
We identified 40,049 unique words in the vocabulary extracted from the processed text of trial registrations. For the binary and word frequency vector representations, the number of features that were shared between training and test sets was 3,513, comprising 8.8% of the 40,049 words (Figure 3) .
For the document similarity methods, the full set of word features with tf-idf weights consistently produced higher levels of performance (Table 1 ). In the best performing methods, half of the correct links could be identified by checking 60 candidates (i.e., median rank of 60), and 60.2% of correct links could be identified by checking 100 candidates.
Matrix factorisation performance
The best performing matrix factorisation approach produced a recall@100 of 75.2% (and a median rank of 36), which was achieved with the PCA feature representation using 200 components with tf-idf weights, and 40 latent factors ( Table 2 ). The LDA feature representation achieved similar results using a similar setup -including 200 topics and 40 latent factors. Increasing the number of components, topics, or latent factors above these levels did not substantially improve the performance. The median rank of the bestperforming matrix factorisation approach was 40% lower and the recall@100 was 25% higher than the best performing document similarity approach.
Comparing the recall@N results across document similarity and matrix factorisation approaches, the matrix factorisation approaches quickly diverge from the document similarity approaches after examining 10 candidates. Using the matrix factorisation approach, a user would need to examine the top 300 candidates to find 90% of the test set, and after examining the top 500 candidates, approximately 95% of the test set would have been found (Figure 4 ).
Tests in a general scenario
The document similarity baseline gave the best performance compared to the matrix factorisation approach in the general scenario, which had fewer training examples. The best-performing document similarity method produced a median rank of 67 (recall@100: 62.9%) using all word features and tf-idf weights and cosine similarity, while the best-performing matrix factorisation approach produced a median rank of 5,124 (recall@100: 1.4%) using LDA with 20 topics and 30 latent factors. As illustrated in Figure 5 for the set of type 2 diabetes reviews, the document similarity approach produced higher recall@100 scores when there were fewer than 10 training examples in the test set of type 2 diabetes reviews.
The results of all experiments have also been made available alongside the source code for the shared latent spaced matrix factorisation method (https://github.com/dsurian/matfac).
DISCUSSION
Our results indicate that a shared latent space matrix factorisation method can support the identification of trial registrations that are relevant to a systematic review. Both the matrix factorisation and document similarity methods could be used together as part of a process to signal when a systematic review is likely to be out of date.
Comparisons with existing research
This is the first study to evaluate matrix factorisation for the purpose of finding new relevant trials from ClinicalTrials.gov for systematic review updates. In terms of manual screening requirements, our findings show that the performance of our tools using this new information source compares favourably to similar methods that operate over bibliographic databases. While the results of studies testing semi-automated screening of published articles for inclusion in systematic reviews are not directly comparable, standard tools in this area use active learning to avoid screening 80% of articles to reach 95% recall [20, 25, 26] . In our results, we were able to reach 95% recall after screening approximately 500 candidates (avoiding 99.6% of the candidate registrations). A recent study using citation links trained on 23 systematic reviews found that to reach 75% recall, the precision dropped to 3.6% [45] , retrieving 300 correct citations after screening 8,298 articles. For our approach trained on 179 systematic reviews, 75% recall was reached after manual screening of 100 trial registrations.
In another recent example, researchers used generalized linear models and gradient boosting machines on 3 systematic reviews, and needed to screen between 192 and 2,112 articles to reach 96% recall [46] . The approach is similar to ours in that it requires knowing which studies were included in existing systematic reviews. However, the approach appears to have used between 6,502 and 41,066 Fig. 4 : Recall@N for various number of candidates that were needed to be checked before the trial registrations included in the type 2 diabetes systematic reviews were found among the set of 128,392 trial registrations.
Implications and recommendations
As policies and practice around the prospective registration and structured results reporting of clinical trials continue to expand, use of trial registries in the production of systematic reviews will likely increase. An important benefit will include earlier identification of when the evidence summarised in a systematic review has become out of date. Tools that automate the identification of relevant trials or dramatically reduce the human workload required in trial selection, could be applied to provide rapid estimates of how much of the available evidence is covered in a published systematic review, thus signalling the need for an update. If an update cannot be produced in a specified time, the systematic review could be flagged as potentially out of date with reference to the new research, in order to inform clinicians and consumers using systematic reviews in their care decisions.
The methods we propose here would benefit from the structured and machine-readable reporting of sets of studies included or excluded from systematic reviews because these would provide a much stronger basis for automating the updating of evidence syntheses. This is evident when comparing the results of the matrix factorisation approach when applied to the type 2 diabetes reviews (where we systematically identified systematic reviews and manually curated a large number of links) and the set of Cochrane reviews, which spanned a number of clinical application domains. While the document similarity approach only uses included trials from one systematic review to find close examples of other trial registrations, the matrix factorisation method uses information from other nearby systematic reviews to learn how to rank registrations. Figure 6 is a t-SNE visualisation [47] of the 128,392 completed trial registrations, illustrating the differences between the 537 trials included in the 179 type 2 diabetes systematic reviews (orange) and the 141 trials included in the 17 Cochrane systematic reviews (blue). In the figure, the position is determined by mapping the feature space into two dimensions such that similar trials are located close together. The matrix factorisation is better able to learn the features that reproduce the known links available in the orange region of this space, and struggles to learn the important features for the Cochrane reviews because the known links are more sparsely distributed across the 128,392 completed trial registrations from Clin-icalTrials.gov.
Limitations
The study has several limitations. First, the set of systematic reviews used in the training and validation of the methods are related to drug interventions in type 2 diabetes -an area with a substantial number of new drugs and a large volume of new trials. This means that the results may not generalise to clinical application domains with fewer trials available, or where trial descriptions are more heterogeneous. Second, our results may underestimate the performance of both the baseline document similarity approach and the matrix factorisation approach because we only used known links to test the performance, and other highly-ranked candidatesespecially those completed since the systematic reviews were published-may also have been relevant but not included in the systematic review.
CONCLUSION
The use of clinical trial registries to monitor which and when systematic reviews require updating has been limited by the extensive manual processes required to identify relevant trial registrations. To date, semi-automated article screening methods used in bibliographic databases have not been extended to trial registries. We found that a matrix factorisation method can be used to rank trial registrations such that 75% of relevant trial registrations will appear within the top 100 candidates, and that the approach worked best when there were at least 10 examples of included trial registrations available for training. The matrix factorisation approach for identifying trials relevant to a systematic review update is likely to be most useful in practice if implemented in a pipeline with other methods designed for scenarios where no or few relevant trial registrations are known. 
